
CLAIMS

We claim:

1. Use of Compound 1 or a pharmaceutically acceptable salt thereof



Compound 1

in the manufacture of a medicament for treating a neurological or psychiatric disease or disorder without decreasing sleep quality, wherein the medicament is a once-daily, oral medicament comprising 25 to 100 mg of Compound 1 to be administered at about bedtime.

2. The use of claim 1, wherein the medicament comprises from 25 to 75 mg of Compound 1.


3. The use of claim 1 or claim 2, wherein the neurological or psychiatric disease or disorder is selected from schizophrenia, depression, and anxiety.

4. The use of any one of claims 1 to 3, wherein the medicament produces a C_{trough} of 7.97-31.5 ng/mL after multiple administrations.

5. The use of any one of claims 1 to 4, wherein the medicament produces a t_{max} of 2.0-4.0 hours after single or multiple administrations.

6. The use of any one of claims 1 to 5, wherein the neurological or psychiatric disease or disorder is to be treated continuously for a period of 6 months or more, and wherein the medicament is to be administered for 6 months or more.

7. Use of Compound 1 or a pharmaceutically acceptable salt thereof



Compound 1

in the manufacture of a medicament for treating a neurological or psychiatric disease or disorder, wherein the medicament is a once-daily medicament to be administered at

about bedtime, wherein the medicament produces a t_{max} of 2.0-4.0 hours after single or multiple administrations.

8. The use of claim 7, wherein the neurological or psychiatric disease or disorder is selected from schizophrenia, depression, and anxiety.

9. The use of claim 7 or claim 8, wherein the medicament comprises from 25 to 75 mg of Compound 1.

10. The use of any one of claims 7 to 9, wherein the medicament produces a C_{trough} of 7.97-31.5 ng/mL after multiple administrations.

11. The use of any one of claims 7 to 10, wherein the neurological or psychiatric disease or disorder is to be treated continuously for a period of 6 months or more, and wherein the medicament is to be administered for 6 months or more.

12. The use of any one of claims 7 to 11, wherein the neurologic or psychiatric disease or disorder is schizophrenia in a patient having a PANSS total score < 80.

13. The use of any one of claims 7 to 11, wherein the neurologic or psychiatric disease or disorder is depression.


14. The use of any one of claims 7 to 11, wherein the neurologic or psychiatric disease or disorder is anxiety.

15. The use of claim 11, wherein the neurologic or psychiatric disease or disorder is schizophrenia in a patient having a PANSS total score < 80.

16. The use of claim 11, wherein the neurologic or psychiatric disease or disorder is depression.

17. The use of claim 11, wherein the neurologic or psychiatric disease or disorder is anxiety.

18. Use of Compound 1 or a pharmaceutically acceptable salt thereof



Compound 1

in the manufacture of a medicament for treating a neurological or psychiatric disease or disorder, wherein the medicament is a once-daily medicament to be administered at about bedtime, wherein the medicament produces a C_{trough} of 7.97-31.5 ng/mL after multiple administrations.

19. The use of claim 18, wherein the neurological or psychiatric disease or disorder is selected from schizophrenia, depression, and anxiety.

20. The use of claim 18 or claim 19, wherein the medicament comprises from 25 to 75 mg of Compound 1.

21. The use of any one of claims 18 to 20, wherein the neurological or psychiatric disease or disorder is to be treated continuously for a period of 6 months or more, and wherein the medicament is to be administered for 6 months or more.